The Lancet Oncology (TLO) For immediate releaseOctober 30, 2002IS PREVENTION REALLY BETTER THAN CURE? Billions of dollars are currently being spent on the search for effective drugs that will stop disease before it happens. Advances in genetic testing are providing more opportunities to find out which diseases people are likely to be at risk of developing-but this knowledge has put huge pressure on the medical profession to come up with ways of avoiding disease altogether. This month`s leading edge questions the ethical issues involved in chemoprevention and highlights the difficulties in obtaining reliable data from chemoprevention clinical trials. It concludes: "Genetic tests have created a demand for chemoprevention that is threatening to push medicine to its limits; health services could be stretched beyond capacity because they are treating healthy people as well as the sick. To stop this snowball effect it is essential that one simple idea is kept in mind: you can spend all the money in the world on preventive medicine, but when people won't even stop smoking, can it really work?" STOMACH CANCER - THE LATEST TARGET FOR THE 'MAGIC BULLET' Gastrointestinal stromal tumours (GISTs) are the most recent cancer type to be targeted by the most effective new drug of recent years-imatinib mesylate. Effective treatment of GISTs has been hindered in the past by their characteristic resistance to conventional chemotherapy and persistent misclassification of these tumours in clinical studies has made pre-2000 data difficult to interpret. However, it is now known that most GISTs contain a mutation in the KIT tyrosine kinase, which means they are an ideal target for imatinib. In their review, Heikki Joensuu and colleagues discuss the recent advances in understanding of these difficult-to-treat tumours and discusses the impact of imatinib on outcome for patients with GISTs. The authors conclude that imatinib "has provided physicians with a well-tolerated and highly effective therapeutic option for a disease for which no systemic therapy existed previously". Imatinib was heralded the "magic bullet" drug after extraordinary success in treatment of chronic myeloid leukaemia, for which it received FDA approval last year. It has also recently been granted FDA approval for the treatment of GISTs. Other reviews: Antisense therapy -- the time of truth Radiation-induced tumour necrosis factor-alpha expression -- clinical application of transcriptional and physical targeting of gene therapy Radiotherapy for cancer of the head and neck -- altered fractionation regimens Totally implantable venous-access ports -- local problems and extravasation injury Lancet |
|||||||||||||||||||||
| Related Cancer Current Events and Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Other Illnesses, Body Weight Do Not Explain Racial Disparities in Colon Cancer Survival, UAB Researchers Say A new study by University of Alabama at Birmingham (UAB) researchers shows that body-mass index (BMI) and co-existing medical conditions (co-morbidity) do not explain the decreased survival observed among African-Americans compared to Caucasians who also have colon cancer. Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." AIDS research reveals a lack of family-planning programs in Uganda University of Alberta graduate student Jennifer Heys wants to make her message clear: there needs to be more education in Ugandan communities about contraception. Possible Link Studied Between Childhood Abuse and Early Cellular Aging Children who suffer physical or emotional abuse may be faced with accelerated cellular aging as adults, according to new research from Butler Hospital and Brown University. Rare pancreatic cancer patients may live longer when treated with radiation therapy Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Saving the single cysteine: new antioxidant system found We've all read studies about the health benefits of having a life partner. The same thing is true at the molecular level, where amino acids known as cysteines are much more vulnerable to damage when single than when paired up with other cysteines. Gene mismatch influences success of bone marrow transplants A commonly inherited gene deletion can increase the likelihood of immune complications following bone marrow transplantation, an international team of researchers reports in the November 22 advance online issue of Nature Genetics. Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||